Abbott’s Wallis trial
This article was originally published in The Gray Sheet
First subject implanted in the U.S. with the firm's Wallis dynamic stabilization spinal implant to treat degenerative disc disease as part of a 340-patient, 20-center clinical trial to support PMA approval. Unlike total disc replacement, such as Johnson & Johnson's Charité, the device does not require an abdominal insertion and does not replace the disc but instead re-routes spinal load through the use of spacers. Abbott acquired Wallis developer Spine Next for $60 mil. in 2004 (1"The Gray Sheet" Nov. 1, 2004, p. 5)...
You may also be interested in...
Abbott Labs will launch a clinical trial early next year supporting a PMA submission for Spine Next's Wallis nonfusion spine stabilization device, having acquired the French manufacturer for $60 mil. and potential milestone payments
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.